UK Approves Antibody-Based GSK Treatment Against Covid-19

The British Medicines Agency (MHRA) announced on Thursday that it approved the treatment of GlaxoSmithKline (GSK) against the coronavirus based on long-acting monoclonal antibodies, a drug that the laboratory emphasizes that it works against the new variant Omicron.

Sotrovimab, the name of the drug, was found to be “safe and effective in reducing the risks of hospitalization and death in people with Covid-19 mild to moderate and at severe risk of developing a severe form of the disease, “the MHRA said in a statement.

GSK said the treatment worked against key mutations in the new Omicron variant.

Currently, sotrovimab has been shown to act against all the worrying and interesting variants defined by the World Health Organization (WHO), “said the laboratory.

According to the MHRA, a single dose of the drug can reduce the risk of hospitalization and death by 79% in infected high-risk adults with symptoms.

The drug was developed in partnership with the Californian laboratory For Biotechnology.

In late June, the European Commission rated the treatment as one of the five most promising against coronavirus.

The sotrovimab It is the second treatment against the coronavirus approved in a month by the United Kingdom, after molnupiravir, tablets from the US laboratory Merck, which received the green light in November.



Reference-www.eleconomista.com.mx

Leave a Comment